ME02193B - Derivati imidazola kao inhibitori enzima pde10a - Google Patents
Derivati imidazola kao inhibitori enzima pde10aInfo
- Publication number
- ME02193B ME02193B MEP-2015-130A MEP13015A ME02193B ME 02193 B ME02193 B ME 02193B ME P13015 A MEP13015 A ME P13015A ME 02193 B ME02193 B ME 02193B
- Authority
- ME
- Montenegro
- Prior art keywords
- group
- compound
- ethyl
- triazolo
- imidazo
- Prior art date
Links
- 239000002532 enzyme inhibitor Substances 0.000 title 1
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 239000003176 neuroleptic agent Substances 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000000626 neurodegenerative effect Effects 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- -1 tetrahydropyran-4-yl-methyl Chemical group 0.000 claims 2
- UXSSEAFAQUPALG-UHFFFAOYSA-N 2-[2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethenyl]-5h-imidazo[2,1-a]isoindole Chemical compound C1=CC=C2C3=NC(C=CC=4N=C5C(C)=NC=C(N5N=4)C)=CN3CC2=C1 UXSSEAFAQUPALG-UHFFFAOYSA-N 0.000 claims 1
- KCEGJZKYKCTWDC-UHFFFAOYSA-N 2-[2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)ethyl]-5h-imidazo[2,1-a]isoindole Chemical compound C1=CC=C2C3=NC(CCC4=NN5C(C)=CC=C(C5=N4)C)=CN3CC2=C1 KCEGJZKYKCTWDC-UHFFFAOYSA-N 0.000 claims 1
- GXEQKJXPCPLDJR-UHFFFAOYSA-N 2-[2-(5-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)ethyl]-5h-imidazo[2,1-a]isoindole Chemical compound C1=CC=C2C3=NC(CCC=4N=C5C=CC=C(N5N=4)C)=CN3CC2=C1 GXEQKJXPCPLDJR-UHFFFAOYSA-N 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- OVGBICIMKVMTBR-UHFFFAOYSA-N 5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound CC1=CN=C(C)C2=NC=NN12 OVGBICIMKVMTBR-UHFFFAOYSA-N 0.000 claims 1
- OONLJFQZTUPWQV-UHFFFAOYSA-N 5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine Chemical compound CC1=CC=C(C)N2N=CN=C12 OONLJFQZTUPWQV-UHFFFAOYSA-N 0.000 claims 1
- HRUGYRNGCHJAHA-UHFFFAOYSA-N 5-methyl-[1,2,4]triazolo[1,5-a]pyridine Chemical compound CC1=CC=CC2=NC=NN12 HRUGYRNGCHJAHA-UHFFFAOYSA-N 0.000 claims 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 229960004372 aripiprazole Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 150000002537 isoquinolines Chemical class 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229950009875 osanetant Drugs 0.000 claims 1
- DZOJBGLFWINFBF-UMSFTDKQSA-N osanetant Chemical compound C([C@](C1)(CCCN2CCC(CC2)(N(C(C)=O)C)C=2C=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CCN1C(=O)C1=CC=CC=C1 DZOJBGLFWINFBF-UMSFTDKQSA-N 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 229960000652 sertindole Drugs 0.000 claims 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41535610P | 2010-11-19 | 2010-11-19 | |
| DKPA201001045 | 2010-11-19 | ||
| EP11793325.9A EP2640731B9 (en) | 2010-11-19 | 2011-11-18 | Imidazole derivatives as pde10a enzyme inhibitors |
| PCT/DK2011/000136 WO2012065612A1 (en) | 2010-11-19 | 2011-11-18 | Imidazole derivatives as pde10a enzyme inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02193B true ME02193B (me) | 2016-02-20 |
Family
ID=45217102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-130A ME02193B (me) | 2010-11-19 | 2011-11-18 | Derivati imidazola kao inhibitori enzima pde10a |
Country Status (32)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8552045B2 (en) | 2010-11-19 | 2013-10-08 | H. Lundbeck A/S | Tricyclic imidazole compounds as PDE10 inhibitors |
| JP6106603B2 (ja) * | 2011-01-11 | 2017-04-05 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヘテロアリール化合物及びその使用方法 |
| WO2013045607A1 (en) * | 2011-09-30 | 2013-04-04 | H. Lundbeck A/S | Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
| WO2013107856A1 (en) * | 2012-01-20 | 2013-07-25 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
| WO2013192273A1 (en) * | 2012-06-19 | 2013-12-27 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| CN103435617B (zh) * | 2013-08-22 | 2016-04-27 | 南京华安药业有限公司 | 一种6,7-二氢-5H-吡咯并[1,2-a]咪唑-2-甲醛的合成方法 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| US10633382B2 (en) | 2016-10-18 | 2020-04-28 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors |
| LT3532064T (lt) | 2016-10-28 | 2020-09-25 | H. Lundbeck A/S | Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui |
| RU2019108717A (ru) | 2016-10-28 | 2020-11-30 | Х. Лундбекк А/С | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов |
| WO2020094591A1 (en) | 2018-11-06 | 2020-05-14 | H. Lundbeck A/S | Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia |
| CN109776527A (zh) * | 2019-02-21 | 2019-05-21 | 药雅科技(上海)有限公司 | 一种5-溴-7-氮杂吲哚的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8307865D0 (en) | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
| US5571775A (en) | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
| IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| EP1641457B1 (en) | 2003-06-30 | 2009-08-05 | Nycomed GmbH | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| MXPA05013553A (es) | 2003-06-30 | 2006-03-09 | Altana Pharma Ag | Pirrolodihidroisoquinolinas como inhibidores de pde10. |
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| EP1723134A2 (en) | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| BRPI0511854A (pt) | 2004-06-07 | 2008-01-15 | Pfizer Prod Inc | inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| CA2578996A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| US8133897B2 (en) * | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| PT2443105E (pt) * | 2009-06-19 | 2015-01-14 | Lundbeck & Co As H | Novo derivado de fenilimidazole como inibidor da enzima pde10a |
| TW201200516A (en) * | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI485151B (zh) * | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
-
2011
- 2011-11-14 JO JOP/2011/0339A patent/JO3089B1/ar active
- 2011-11-15 TW TW100141570A patent/TWI541245B/zh not_active IP Right Cessation
- 2011-11-18 PE PE2013001212A patent/PE20141534A1/es active IP Right Grant
- 2011-11-18 SG SG2013037163A patent/SG190282A1/en unknown
- 2011-11-18 EA EA201390741A patent/EA027082B1/ru not_active IP Right Cessation
- 2011-11-18 AR ARP110104313A patent/AR083926A1/es unknown
- 2011-11-18 AU AU2011331607A patent/AU2011331607B2/en not_active Ceased
- 2011-11-18 CN CN201180065325.2A patent/CN103328487B/zh not_active Expired - Fee Related
- 2011-11-18 BR BR112013012378A patent/BR112013012378A2/pt not_active Application Discontinuation
- 2011-11-18 UA UAA201307630A patent/UA112065C2/uk unknown
- 2011-11-18 SI SI201130586T patent/SI2640731T1/sl unknown
- 2011-11-18 ME MEP-2015-130A patent/ME02193B/me unknown
- 2011-11-18 DK DK11793325.9T patent/DK2640731T3/en active
- 2011-11-18 RS RS20150574A patent/RS54210B1/sr unknown
- 2011-11-18 ES ES11793325.9T patent/ES2547090T3/es active Active
- 2011-11-18 PH PH1/2013/500968A patent/PH12013500968A1/en unknown
- 2011-11-18 AP AP2013006928A patent/AP3342A/xx active
- 2011-11-18 KR KR1020137012797A patent/KR101916487B1/ko not_active Expired - Fee Related
- 2011-11-18 CA CA2817663A patent/CA2817663C/en not_active Expired - Fee Related
- 2011-11-18 NZ NZ610353A patent/NZ610353A/en not_active IP Right Cessation
- 2011-11-18 PL PL11793325T patent/PL2640731T3/pl unknown
- 2011-11-18 MY MYPI2013001727A patent/MY163327A/en unknown
- 2011-11-18 EP EP11793325.9A patent/EP2640731B9/en active Active
- 2011-11-18 GE GEAP201113117A patent/GEP20156346B/en unknown
- 2011-11-18 JP JP2013539140A patent/JP5937608B2/ja not_active Expired - Fee Related
- 2011-11-18 WO PCT/DK2011/000136 patent/WO2012065612A1/en not_active Ceased
- 2011-11-18 HU HUE11793325A patent/HUE025596T2/en unknown
- 2011-11-18 PT PT117933259T patent/PT2640731E/pt unknown
-
2013
- 2013-05-16 GT GT201300130A patent/GT201300130A/es unknown
- 2013-05-16 CR CR20130226A patent/CR20130226A/es unknown
- 2013-05-17 ZA ZA2013/03607A patent/ZA201303607B/en unknown
- 2013-06-18 EC ECSP13012698 patent/ECSP13012698A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542963A5 (enExample) | ||
| CA2783727A1 (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
| NZ600365A (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors | |
| HRP20140232T1 (hr) | Novi derivati fenilimidazola kao inhibitori enzima pde10a | |
| HRP20140898T1 (hr) | Heteroaromatski derivati fenilimidazola kao inhibitori enzima pde10a | |
| US9157077B2 (en) | Aminopyrimidine kinase inhibitors | |
| US10736893B2 (en) | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | |
| CA3139769A1 (en) | Nitrogen-containing heterocyclic derivative regulator, preparation method therefor and application thereof | |
| NZ610353A (en) | Imidazole derivatives as pde10a enzyme inhibitors | |
| NZ599932A (en) | Imidazopyridine derivatives as jak inhibitors | |
| GEP20105054B (en) | Imidazoquinolines as lipid kinase inhibitors | |
| TN2011000339A1 (en) | Poly (adp-ribose) polymerase (parp) inhibitors | |
| NZ630721A (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| NZ598907A (en) | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors | |
| EP2288260A4 (en) | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD | |
| JP2012514601A5 (enExample) | ||
| US20190314369A1 (en) | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | |
| NZ605889A (en) | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors | |
| ME00230B (me) | 2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni | |
| MX2008013578A (es) | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). | |
| US20180030054A1 (en) | Novel inhibitor of flt3 kinase and use thereof | |
| NZ601077A (en) | Use of an adrenal hormone-modifying agent | |
| RU2010119934A (ru) | Производные 6-арил/гетероалкилокси бензотиазола и бензимидазола, способ их получения, их применение в качестве лекарственных средств, фармацевтические композиции и новое применение, в частности, в качестве ингибиторов смет | |
| WO2020069418A1 (en) | Small molecule inhibitors of dyrk1/clk and uses thereof | |
| PH12015501836A1 (en) | 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors |